Longeveron Inc. (LGVN): Capital Expenditures
$245.0K
Year ended 2025-12-31
$160.0K
Trailing 12 months to 2026-06-30
-24.5%
3-year compound annual growth
+13.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $245.0K | -62.6% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $655.0K | +117.6% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $301.0K | -47.1% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $569.0K | +72.4% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $330.0K | +151.9% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $131.0K | n/a | 2022-03-11, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Longeveron Inc. (LGVN) | 2025-12-31 | $245.0K | -62.6% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2025-03-31 | $2.0K | -71.4% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $112.0K | -18.8% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $600.0K | n/a |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $5.5K | n/a |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $1.50M | +48.3% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $385.3K | -32.8% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $139.9K | +34.8% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $71.0K | +20.3% |
Compare LGVN, SXTC, IGC, BSPK side by side · Screen every company in Pharmaceutical Preparations ↗